Ameritas Investment Partners, Inc. - LINEAGE CELL THERAPEUTICS IN ownership

LINEAGE CELL THERAPEUTICS IN's ticker is LCTX and the CUSIP is 53566P109. A total of 105 filers reported holding LINEAGE CELL THERAPEUTICS IN in Q3 2023. The put-call ratio across all filers is - and the average weighting 0.1%.

Quarter-by-quarter ownership
Ameritas Investment Partners, Inc. ownership history of LINEAGE CELL THERAPEUTICS IN
ValueSharesWeighting
Q3 2023$12,574
-16.3%
10,6560.0%0.00%0.0%
Q2 2023$15,025
+0.2%
10,656
+12.1%
0.00%0.0%
Q1 2022$15,000
-34.8%
9,5080.0%0.00%0.0%
Q4 2021$23,000
-4.2%
9,5080.0%0.00%0.0%
Q3 2021$24,000
-11.1%
9,5080.0%0.00%0.0%
Q2 2021$27,000
+440.0%
9,508
+58.3%
0.00%
Q1 2020$5,0000.0%6,0050.0%0.00%
Q4 2019$5,000
-16.7%
6,0050.0%0.00%
Q3 2019$6,0006,0050.00%
Other shareholders
LINEAGE CELL THERAPEUTICS IN shareholders Q3 2023
NameSharesValueWeighting ↓
Defender Capital, LLC. 4,735,990$8,335,0003.63%
BROADWOOD CAPITAL INC 34,005,379$59,849,0003.55%
Prescott General Partners LLC 1,851,851$3,259,0000.14%
Strategic Wealth Investment Group, LLC 66,917$118,0000.07%
Laidlaw Wealth Management LLC 170,658$300,0000.06%
Humankind Investments LLC 26,737$47,0000.05%
DAFNA Capital Management LLC 80,000$141,0000.04%
Beirne Wealth Consulting Services, LLC 45,000$79,0000.04%
BRIDGEWAY CAPITAL MANAGEMENT, LLC 680,839$1,198,0000.02%
Allegheny Financial Group LTD 20,000$35,0000.02%
View complete list of LINEAGE CELL THERAPEUTICS IN shareholders